Published November 6, 2017 | Version v1
Journal article

First intraindividual comparison of contrast-enhanced MRI, FET- and DOTATOC- PET in patients with intracranial meningiomas

  • 1. Department of Radiation Oncology, University Hospital of Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg (Germany)
  • 2. Department of Radiation Oncology, Klinikum rechts der Isar, Technische Universität München (TUM), Ismaninger Str. 22, 81675 Munich (Germany)
  • 3. Department of Nuclear Medicine, University Hospital of Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg (Germany)
  • 4. Deutsches Konsortium für Translationale Krebsforschung (DKTK), Partner Site Munich, Munich (Germany)
  • 5. Institute for Innovative Radiotherapy (iRT), Department of Radiation Sciences (DRS), Helmholtz Zentrum München, 85764 Oberschleißheim (Germany)

Description

For irradiation treatment planning of meningiomas the use of PET-scans is well established. The most frequently used tracers are either based on amino acids or the somatostatin receptor ligand DOTATOC. Since up to now no inter-institutionally accepted standard PET-tracer has been defined, the aim of this study was to evaluate the influence of these different types of PET-tracers on the GTV-definition. Twenty-one patients suffering from intracranial meningiomas underwent CT, MRI, FET- and DOTATOC-PET. First, tumour extension was delineated after image-fusion of CT and MRI (GTVCT/MRI). Then distinct GTVs based either on FET- or DOTATOC-PET were contoured and compared with each other as well with GTVCT/MRI. Every tumour showed typical enhancement of DOTATOC, but two meningiomas remained FET-negative. The mean relative overlap volume of GTVFET and GTVDOTATOC was only 41.9% and there was a significantly stronger correlation between GTVCT/MRI and GTVDOTATOC than between GTVCT/MRI and GTVFET. Further investigations are necessary to clarify the minor conformity of DOTATOC- and FET-PET in meningiomas. Because of the receptor targeting, DOTATOC is known to be more specific for meningiomas and will remain the standard in our institution with the known limitation in areas nearby the pituitary gland.

Availability note (English)

Available from http://dx.doi.org/10.1186/s13014-017-0913-x; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5674744

Additional details

Identifiers

Publishing Information

Journal Title
Radiation Oncology (Online)
Journal Volume
12
Journal Page Range
vp.
ISSN
1748-717X

INIS

Country of Publication
United Kingdom
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
49082472
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
NMR IMAGING; PATIENTS; PITUITARY GLAND; POSITRON COMPUTED TOMOGRAPHY
Descriptors DEC
BODY; COMPUTERIZED TOMOGRAPHY; DIAGNOSTIC TECHNIQUES; EMISSION COMPUTED TOMOGRAPHY; ENDOCRINE GLANDS; GLANDS; ORGANS; TOMOGRAPHY

Optional Information

Copyright
Copyright (c) The Author(s). 2017
Notes
PMCID: PMC5674744; PMID: 29110720; PUBLISHER-ID: 913; OAI: oai:pubmedcentral.nih.gov:5674744